CI

At a glance

ClinicalIndex Comparison Record
Phase 1Enrolling by Invitation· 10 target
Drug / intervention
Immunomodulatory DC vaccine to target DIPG and GBMbiological
Likely dose
Immunomodulatory DC vaccine to target DIPG and GBM 200 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03914768
NCT03914768Phase 1Enrolling by InvitationMonitor
Slow Enrollment
CompareCT.gov

Immune Modulatory DC Vaccine Against Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma (GBM)

Shenzhen Geno-Immune Medical Institute·interventional·Posted Apr 16, 2019·Updated Jun 23, 2026

In Brief

A Phase 1 clinical trial evaluating Immunomodulatory DC vaccine to target DIPG and GBM for Diffuse Intrinsic Pontine Glioma or Glioblastoma. Currently enrolling by invitation, targeting 10 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

This study is designed to treat patients who have been diagnosed with brain cancer, including glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The treatment uses immunomodulatory vaccine generated by autologous dendritic cells (DCs) pulsed with genetically modified tumor cells or tumor-related antigens including neoantigens to inject into patients. Vaccine-induced T cell responses have been associated with improved survival. The study will evaluate the safety and potential benefit of the novel immunomodulatory DC vaccines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Intrinsic Pontine Glioma or Glioblastoma
CountriesChina
Collaborators--

Timeline

Phase 1Enrolling by Invitation
201920202021202220232024202520262027202820292030
First PostedApr 16, 2019
Enrollment StartMay 31, 2026
Primary CompletionMay 31, 2029
Study CompletionDec 31, 2029
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 7.2 years agoPrimary completion in 2.9 years

Arms & Interventions

Immunomodulatory DC vaccine to target DIPG and GBMexperimental

Patients will receive immune modulatory treatment consisting of cyclophosphamide (200 mg/m2) and bevacizumab (15 mg/kg), before and after DC vaccine injection, respectively.

Biological: Immunomodulatory DC vaccine to target DIPG and GBM

Interventions

Immunomodulatory DC vaccine to target DIPG and GBMbiological

This study will inject DC vaccine cells near lymphoid tissue close to the tumor. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg) the next day. The cells will be repeatedly infused every month for six consecutive months depending on the response and the condition of the patient. The amount of DC vaccine cells per injection is based on prior report at 5-10x106. An initial dose escalation scheme will be imposed.